Rhetorical Strategies Used in the Reporting of Implantable Defibrillator Primary Prevention Trials

被引:7
|
作者
Wilson, John R.
机构
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2011年 / 107卷 / 12期
关键词
CARDIOVERTER-DEFIBRILLATOR; DILATED CARDIOMYOPATHY; PROPHYLACTIC USE; HIGH-RISK; AMIODARONE; DEATH;
D O I
10.1016/j.amjcard.2011.02.320
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Previous studies have suggest that the authors of randomized trial reports frequently use rhetorical strategies, such as framing, the use of ratios rather than absolute values to report results, and underreporting of complications, to convince readers of treatment efficacy. The objective of this study was to determine if such rhetorical strategies were used in the publication of implantable-cardioverter defibrillator (ICD) primary prevention trials. Med-line and the Cochrane Central Register Of Controlled Trials were searched for all publications that described ICD primary prevention trials and that involved > 100 subjects. Each publication was analyzed for evidence of message framing, the exclusive use of ratios to report outcomes, underreporting of ICD complications, and interpretation bias favoring ICD therapy. Ten publications were identified. Introductory remarks in 8 of the 10 publications cited the evaluation of ICD benefits as the sole objective and mentioned only background studies that supported ICD efficacy, suggesting message framing in support of ICD efficacy. Five publications provided no specific information about the frequency of unsuccessful ICD implantations, and 8 publications provided incomplete or no information about implantation and postimplantation complications. ICD complications were not mentioned in the discussion sections of 9 publications, and none of the publications included a comprehensive comparison of ICD benefits versus risks, consistent with interpretation bias. Ratios and statistically insignificant data were not used to emphasize ICD benefits. In conclusion, message framing, underreporting of ICD complications, and interpretation bias were used to emphasize ICD efficacy in the reporting of ICD primary prevention trials. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;107:1806-1811)
引用
收藏
页码:1806 / 1811
页数:6
相关论文
共 50 条
  • [11] THE ECONOMIC IMPACT OF THE USE OF IMPLANTABLE CARDIOVERTER DEFIBRILLATOR IN PRIMARY PREVENTION
    Madotto, F.
    Conti, S.
    Chiodini, V
    Mantovani, L. G.
    Achilli, F.
    Curnis, A.
    Landolina, M.
    Lunati, M.
    Marzegalli, M.
    Proclemer, A.
    Fornari, C.
    Cesana, G.
    VALUE IN HEALTH, 2015, 18 (07) : A337 - A337
  • [12] Clinical strategies for use of the implantable cardioverter defibrillator: The impact of current trials
    Estes, NAM
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1996, 19 (07): : 1011 - 1015
  • [13] Survival of Patients Receiving a Primary Prevention Implantable Cardioverter-Defibrillator in Clinical Practice vs Clinical Trials
    Al-Khatib, Sana M.
    Hellkamp, Anne
    Bardy, Gust H.
    Hammill, Stephen
    Hall, W. Jackson
    Mark, Daniel B.
    Anstrom, Kevin J.
    Curtis, Jeptha
    Al-Khalidi, Hussein
    Curtis, Lesley H.
    Heidenreich, Paul
    Peterson, Eric D.
    Sanders, Gillian
    Clapp-Channing, Nancy
    Lee, Kerry L.
    Moss, Arthur J.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (01): : 55 - 62
  • [14] Underutilization of Implantable Cardioverter Defibrillator in Primary Prevention of Sudden Cardiac Arrest
    Lakshmanadoss, Umashankar
    Sherazi, Saadia
    Aggarwal, Ashim
    Hsi, David
    Aktas, Mehmet K.
    Daubert, James P.
    Shah, Abrar H.
    CARDIOLOGY RESEARCH, 2011, 2 (01) : 1 - 6
  • [15] The implantable cardioverter defibrillator in primary prevention: a revision of monocentric study group
    Gigli, L.
    Barabino, D.
    Sartori, P.
    Rossi, P.
    Reggiardo, G.
    Chiarella, F.
    Rosa, G. M.
    Bertero, G.
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2014, 15 (08) : 653 - 658
  • [16] Latest data from secondary prevention implantable cardioverter-defibrillator trials
    Naccarelli, G
    Oseroff, O
    CLINICAL CARDIAC PACING AND ELECTROPHYSIOLOGY, 2003, : 965 - 973
  • [17] What reduction in mortality can we expect from the ongoing primary prevention implantable cardioverter-defibrillator trials?
    Brüggemann, T
    Ehlers, C
    Andresen, D
    EUROPEAN HEART JOURNAL, 2002, 23 : 7 - 7
  • [18] Update on implantable cardioverter defibrillator trials
    Shah A.H.
    Huang D.T.
    Rosero S.Z.
    Daubert J.P.
    Current Cardiology Reports, 2004, 6 (5) : 327 - 332
  • [19] A review of the implantable cardioverter defibrillator trials
    Cannom, DS
    CURRENT OPINION IN CARDIOLOGY, 1998, 13 (01) : 3 - 8
  • [20] Assessment of Implantable Cardioverter-Defibrillator Used in Heart Failure with Reduced Ejection Fraction as Primary Prevention in an Underserved Population
    Lu, Yifan
    Wan, Ningxin
    Madan, Nidhi
    Hovnanians, Ninel
    Diaz, Juan Carlos Ruiz
    Christia, Panagiota
    Faillace, Robert
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2018, 33 (11) : 1854 - 1856